NCT06390722: A trial that was reported late by AbbVie
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06390722 |
|---|---|
| Title | A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Upadacitinib on Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (SLEEP UP) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 23, 2024 |
| Completion date | Jan. 5, 2026 |
| Required reporting date | Jan. 5, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 17, 2025 |
| Days late | None |